HYBRID EVENT: You can participate in person at Rome, Italy or Virtually from your home or work.
3rd Edition of
International Ophthalmology Conference
March 10-12, 2025 | Rome, Italy
Ocular Oncology and Eye Tumours
Ocular Oncology and Eye Tumours
Ocular tumors, often known as eye tumors, are tumors that affect the eyes. A tumor is a collection of abnormally growing cells that can be either malignant (cancerous) or benign (non-cancerous) (noncancerous). Metastatic eye tumors are the most prevalent type of eye tumor. The study and treatment of cancers in or around the eye is referred to as ocular oncology. These tumors can range from benign to life-threatening, and they can result in vision loss or the loss of the eye itself. Ocular care for people with eye cancer is a unique field. Certainly, the difficulties encountered are not the same as those encountered in a regular ophthalmic practice.
- Biomarkers and Early Detection of Cancers
- Adjuvant Therapies
- Improved Visual Outcomes After Ocular Melanoma Treatment
- Clinical Care
- Types of Ocular Tumors
- Challenges of Ocular Oncology
Committee Members
John David Bullock
Wright State University, United States
Edward Charles Kondrot
Healing the Eye Wellness Center, United States
Minckler Don S
UCI Gavin Herbert Eye Institute, United States IOC 2025 Speakers
Dhruva Drew Gupta
Harvard Medical School, United States
Nour Abou Shousha
Harvard Medical School, United States
George HH Beiko
McMaster Univeresity, Canada
Mustafa Al Ghazi
University Hospital of Wales, United KingdomSubmit your abstract Today
Title : Optic nerve orthograde axonal transport in abusive head trauma suspects
Minckler Don S, UCI Gavin Herbert Eye Institute, United States
Title : Eyes and guts connection: Microbiomes and their role in ocular health
Edward Charles Kondrot, Healing the Eye Wellness Center, United States
Title : Why was Leonhard Euler blind?
John David Bullock, Wright State University, United States
Title : Ultra-widefield protocol enhances automated classification of diabetic retinopathy severity with OCT angiography
Kasra Rezaei, University of Washington, United States
Title : A factorial randomized controlled trial of tissue plasminogen activator and/or perfluoropropane for the treatment of submacular hemorrhage secondary to neovascular age-related macular degeneration (TAPAS)
Tim Jackson, King’s College London, United Kingdom
Title : Developing resilience-based treatments for glaucoma
Simon John, Columbia University, United States